To date, the largest cost burden in the cultivating meat industry is the culture media used to grow meat cells. The goal of the recently formed CMMC from industry and academia is to address challenges in cultivated meat industry through the application of computer modeling and simulation. Insilico brings its Digital Twins technology to the CMMC to optimize culture media composition and feeding strategies, thus reducing these costs and making commercial production of clean meat economically feasible.
There are many challenges impeding commercial production of clean meat. One major challenge is a need to balance the cells’ consumption of expensive nutrients to produce meat at a competitive price. This requires the smart design of nutrient composition in the culture media to just meet the needs of the cells. Thus, growth is maximized without accumulation of excess nutrients in the media.
Another challenge is the need to create large quantities of meat. In most laboratories, only small-scale experiments are performed to demonstrate feasibility. On the much larger scale required for commercial production, the mixing behavior of media and cell culture differ drastically, which can lead to cells becoming detached from carrier materials and a local shortage of vital oxygen. Creating large quantities requires translating laboratory successes to this different environment, yet physical experimentation is cost-prohibitive. Computer models of behavior at laboratory scale are simulated and validated. Running many small-scale simulations then generates data that can be used to estimate larger-scale behaviors using model components that form digital twins.
Insilico Biotechnology brings in its many years of expertise in metabolic modeling to determine the most efficient growth conditions while other partners contribute complementary components as needed to model large production facilities. The overall system is intended to optimize the feeding of the cells, the nature of the cellular carrier material, and the cultivation mixing through millions of simulation studies.
Klaus Mauch, the CEO of Insilico, says: "We anticipate that cultivated meat production on a commercial scale would be a promising solution to meet the increasing demand for proteins by the growing world population", and adds: “We are pleased to use our experience in cell culture feeding and media design to contribute along with the CMMC to overcome the high production cost of cultivated meat making it affordable.”
About The CMMC
The Cultivated Meat Modeling Consortium (CMMC) is a wholly-owned subsidiary of Biocellion SPC, a Washington State Social Purpose Corporation. Founded by Dr. Simon Kahan, the CMMC mission is to accelerate progress in cultivated meat through the application and development of computer modeling and simulation. The CMMC vision brings together diverse stakeholders, who subscribe to this mission to form a community self-managed by a working group composed of its members, to work on projects. CMMC subscriptions include sustaining members who contribute funds in exchange for a discount on licensing CMMC IP; commercial industry members who contribute industry insight in exchange for influencing CMMC project priorities toward what they themselves need; purpose-aligned non-profit industry members who provide connections and domain expertise in exchange for multiplying their social impact; and solution provider members who contribute new IP created jointly with other members or through projects in exchange for a percentage of the licensing revenue it generates.
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Ground breaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany